NFE2L2 and inflammation: Here, we provide, to our best knowledge, the first experimental evidence suggesting that FGS pretreatment protected from acute neutrophilic lung inflammation, the hallmark of ALR/ARDS, and that FGS activated an anti-inflammatory factor Nrf2 without affecting NF-κB activity.